Author/Authors :
Rha، نويسنده , , Seung-Woon and Kuchulakanti، نويسنده , , Pramod K. and Pakala، نويسنده , , Rajbabu and Cheneau، نويسنده , , Edouard and Pinnow، نويسنده , , Ellen and Torguson، نويسنده , , Rebecca and Pichard، نويسنده , , Augusto D. and Satler، نويسنده , , Lowell F. and Suddath، نويسنده , , William O. and Kent، نويسنده , , Kenneth M. and Lindsay، نويسنده , , Joseph and Waksman، نويسنده , , Ron، نويسنده ,
Abstract :
Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions, and data on its usage in saphenous vein graft interventions are limited. This retrospective, observational study evaluated the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients who underwent saphenous vein graft intervention with distal protection devices. We found that bivalirudin use is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
